Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models.
about
Epigenetic modulators as therapeutic targets in prostate cancerPrediction of novel drug indications using network driven biological data prioritization and integration.Novel targeted therapeutics for metastatic castration-resistant prostate cancer.Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models.Exploiting Epigenetic Alterations in Prostate Cancer.Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiationEpigenetics in prostate cancer.Long-lasting reduction in clonogenic potential of colorectal cancer cells by sequential treatments with 5-azanucleosides and topoisomerase inhibitors.The chemomodulatory effects of glufosfamide on docetaxel cytotoxicity in prostate cancer cells.Vitamin E δ-tocotrienol triggers endoplasmic reticulum stress-mediated apoptosis in human melanoma cells.Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells.Decitabine impact on the endocytosis regulator RhoA, the folate carriers RFC1 and FOLR1, and the glucose transporter GLUT4 in human tumors.The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma.Future directions in castrate-resistant prostate cancer therapy.Hypomethylating agents for urologic cancers.Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer.Novel anti-cancer compounds for developing combinatorial therapies to target anoikis-resistant tumors.Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC).The methylation landscape of tumour metastasis.Nephrotoxicity of epigenetic inhibitors used for the treatment of cancer.Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth.Antitumor effects of saffron-derived carotenoids in prostate cancer cell models.Phase I Study of Epigenetic Priming with Azacitidine Prior to Standard Neoadjuvant Chemotherapy for Patients with Resectable Gastric and Esophageal Adenocarcinoma: Evidence of Tumor Hypomethylation as an Indicator of Major Histopathologic Response.Endoplasmic reticulum protein ERp46 in prostate adenocarcinoma.Incorporating DNA Methyltransferase Inhibitors (DNMTis) in the Treatment of Genitourinary Malignancies: A Systematic Review.Additive naftopidil treatment synergizes docetaxel-induced apoptosis in human prostate cancer cells.SDHB downregulation facilitates the proliferation and invasion of colorectal cancer through AMPK functions excluding those involved in the modulation of aerobic glycolysis.Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia.Targeting DNA Methyltranferases in Urological Tumors.
P2860
Q28071912-9F735F5A-36CF-402C-A841-C1293B0CCBBEQ30727519-99524085-34B5-4266-A0AE-57640FBACC83Q33642278-AE84F491-7E08-4E19-9842-1E4EEDCE343AQ33728180-D1C248D4-398A-41A6-9803-A9214214B036Q33755160-A5346016-0C98-4BD7-8317-E233E627D76EQ34405013-2B2C7999-7D42-4EED-9363-E4685BCD179EQ35608952-0216A42A-84C4-458A-B520-1ACC9C145DE3Q36194410-88852E20-A7CF-4F9A-9CBD-2F14B8FB8C11Q37065525-ADFAB088-EEF8-4E6A-A04B-C4F5C61D082EQ37200271-F16EDAF2-7BF6-4F29-ACC6-6DF1A3F33182Q37463725-CC465A3A-280E-4DD2-BBE7-A364A5729ADEQ37493954-6EF1B1DD-69D2-4626-B5BE-8EDD28DCD957Q37567174-BE77940E-DF76-4415-BEDE-BFFB45491EDDQ37826274-57019C97-86E3-4B94-A0FD-57F7248775ECQ37854737-40F1448B-6F58-4CEB-B2D4-4AC2D65306A7Q37876194-6556F51A-F68A-4F66-BB39-A7F49B45932BQ37971860-17352953-EB51-4B15-B8B6-BF0A64A7405DQ38044064-21F93327-99E5-4562-B2FC-99D7C0179C4BQ38063931-351D4A42-3D12-43D1-9883-CAC97C77AD1DQ38750965-1DE72BA9-C521-487C-B8E1-DF34F8863AD2Q39660971-83A79ACF-ED69-40C8-B105-C1ABBEA7862EQ40029476-0485F802-887D-4EA7-AF7C-667A74C83622Q40419898-96D88333-FEBF-4F0B-A97B-6823B6A1F916Q41811207-F82D512C-124A-485E-B0AF-17FBCF8A3D3BQ48136845-9794CB6B-FD00-4AF7-8616-F9905200810EQ48371276-C690ADF4-F539-4F1F-AFDF-A4D14EC4D810Q49335595-4B9CAFEE-AFA1-4B19-B5EB-D0313D549BB5Q54686060-04804298-C600-4ACB-A9C4-BCD47894306AQ55435258-6DF0C2AF-7DAD-4642-BEA5-254D8E6F8CF4
P2860
Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Azacitidine improves antitumor ...... essive prostate cancer models.
@en
Azacitidine improves antitumor ...... essive prostate cancer models.
@nl
type
label
Azacitidine improves antitumor ...... essive prostate cancer models.
@en
Azacitidine improves antitumor ...... essive prostate cancer models.
@nl
prefLabel
Azacitidine improves antitumor ...... essive prostate cancer models.
@en
Azacitidine improves antitumor ...... essive prostate cancer models.
@nl
P2093
P50
P356
P1476
Azacitidine improves antitumor ...... essive prostate cancer models.
@en
P2093
Anna Maria D'Alessandro
Claudio Festuccia
Danilo Millimaggi
Paola Muzi
P304
P356
10.1677/ERC-08-0130
P577
2009-01-19T00:00:00Z